Characterisation of C5a receptor agonists from phage display libraries

Biochemical Pharmacology

Volumn 66, Issue 9, 2003, Pages 1833-1840

  Cain, Stuart A ^a   Higginbottom, Adrian ^a   Monk, Peter N ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

8 Oxodeoxyguanosine; Complement receptor; PCR; Phage display; Pyrimidine analogue; Random mutagenesis

Indexed keywords

COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; MUTANT PROTEIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; GENE LIBRARY; GENE MUTATION; HYDROPHOBICITY; HYPOTHESIS; LEUKEMIA CELL; MALE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; RAT; RECEPTOR BINDING;

EID: 0141922889     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00473-8     Document Type: Article

References (27)

1. Arumugam T.V., Shiels I.A., Strachan A.J., Abbenante G., Fairlie D.P., Taylor S.M. A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int. 63:2003;134-142.
2. Heller T., Hennecke M., Baumann U., Gessner J.E., zu Vilsendorf A.M., Baensch M., Boulay F., Kola A., Klos A., Bautsch W., Kohl J. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. J. Immunol. 163:1999;985-994.
3. Riley R.D., Sato H., Zhao Z.Q., Thourani V.H., Jordan J.E., Fernandez A.X., Ma X.L., Hite D.R., Rigel D.F., Pellas T.C., Peppard J., Bill K.A., Lappe R.W., Vinten-Johansen J. Recombinant human complement C5a receptor antagonist reduces infarct size after surgical revascularization. J. Thorac. Cardiovasc. Surg. 120:2000;350-358.
4. Strachan A.J., Woodruff T.M., Haaima G., Fairlie D.P., Taylor S.M. A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. J. Immunol. 164:2000;6560-6565.
5. Woodruff T.M., Strachan A.J., Dryburgh N., Shiels I.A., Reid R.C., Fairlie D.P., Taylor S.M. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monoarticular arthritis in the rat. Arthritis Rheum. 46:2002;2476-2485.
6. Mollison K.W., Mandecki W., Zuiderweg E.R., Fayer L., Fey T.A., Krause R.A., Conway R.G., Miller L., Edalji R.P., Shallcross M.A., Lane B., Fox J.L., Greer J., Carter G.W. Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. Proc. Natl. Acad. Sci. U.S.A. 86:1989;292-296.
7. Bubeck P., Grotzinger J., Winkler M., Kohl J., Wollmer A., Klos A., Bautsch W. Site-specific mutagenesis of residues in the human C5a anaphylatoxin which are involved in possible interaction with the C5a receptor: identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. Eur. J. Biochem. 219:1994;897-904.
8. Toth M.J., Huwyler L., Boyar W.C., Braunwalder A.F., Yarwood D., Hadala J., Haston W.O., Sills M.A., Seligmann B., Galakatos N., Bubeck P., Grotzinger J., Winkler M., Kohl J., Wollmer A., Klos A., Bautsch W. The pharmacophore of the human C5a anaphylatoxin. Protein Sci. 3:1994;1159-1168.
9. Bokisch V.A., Muller-Eberhard H.J. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J. Clin. Invest. 49:1970;2427-2436.
10. Eglite S., Pluss K., Dahinden C.A. Requirements for C5a receptor-mediated IL-4 and IL-13 production and leukotriene C4 generation in human basophils. J. Immunol. 165:2000;2183-2189.
11. Monk P.N., Pease J.E., Barker M.D. C5a stimulus-secretion coupling in rat basophilic leukaemia (RBL-2H3) cells transfected with the human C5a receptor is mediated by pertussis and cholera toxin-sensitive G proteins. Biochem. Mol. Biol. Int. 32:1994;13-20.
12. Crass T., Bautsch W., Cain S.A., Pease J.E., Monk P.N. Receptor activation by human C5a des Arg74 but not intact C5a is dependent on an interaction between Glu199 of the receptor and Lys68 of the ligand. Biochemistry. 38:1999;9712-9717.
13. Cain S.A., Coughlan T., Monk P.N. Mapping the ligand-binding site on the C5a receptor: arginine74 of C5a contacts aspartate282 of the C5a receptor. Biochemistry. 40:2001;14047-14052.
14. Cain S.A., Woodruff T.M., Taylor S.M., Fairlie D.P., Sanderson S.D., Monk P.N. Modulation of ligand selectivity by mutation of the first extracellular loop of the human C5a receptor. Biochem. Pharmacol. 61:2001;1571-1579.
15. Sun J., Ember J.A., Chao T.H., Fukuoka Y., Ye R.D., Hugli T.E. Identification of ligand effector binding sites in transmembrane regions of the human G protein-coupled C3a receptor. Protein Sci. 8:1999;2304-2311.
16. Cain S.A., Ratcliffe C.F., Williams D.M., Harris V., Monk P.N. Analysis of receptor/ligand interactions using whole-molecule randomly-mutated ligand libraries. J. Immunol. Methods. 245:2000;139-145.
17. Cain S.A., Williams D.M., Harris V., Monk P.N. Selection of novel ligands from a whole-molecule randomly mutated C5a library. Protein Eng. 14:2001;189-193.
18. Zaccolo M., Williams D.M., Brown D.M., Gherardi E. An approach to random mutagenesis of DNA using mixtures of triphosphate derivatives of nucleoside analogues. J. Mol. Biol. 255:1996;589-603.
19. Paczkowski N.J., Finch A.M., Whitmore J.B., Short A.J., Wong A.K., Monk P.N., Cain S.A., Fairlie D.P., Taylor S.M. Pharmacological characterization of antagonists of the C5a receptor. Br. J. Pharmacol. 128:1999;1461-1466.
20. Hennecke M., Otto A., Baensch M., Kola A., Bautsch W., Klos A., Kohl J. A detailed analysis of the C5a anaphylatoxin effector domain: selection of C5a phage libraries on differentiated U937 cells. Eur. J. Biochem. 252:1998;36-44.
21. Kola A., Baensch M., Bautsch W., Klos A., Kohl J. Analysis of the C5a anaphylatoxin core domain using a C5a phage library selected on differentiated U937 cells. Mol. Immunol. 36:1999;145-152.
22. Cain S.A., Williams D.M., Harris V., Monk P.N. Selection of novel ligands from a whole-molecule randomly mutated C5a library. Protein Eng. 14:2001;189-193.
23. Monk P.N., Barker M.D., Partridge L.J., Pease J.E. Mutation of glutamate 199 of the human C5a receptor defines a binding site for ligand distinct from the receptor N terminus. J. Biol. Chem. 270:1995;16625-16629.
24. Hennecke M., Kola A., Baensch M., Wrede A., Klos A., Bautsch W., Kohl J. A selection system to study C5a-C5a-receptor interactions: phage display of a novel C5a anaphylatoxin, Fos-C5aAla27. Gene. 184:1997;263-272.
25. Bugli F., Bastidas R., Burton D.R., Williamson R.A., Clementi M., Burioni R. Molecular profile of a human monoclonal antibody Fab fragment specific for Epstein-Barr virus gp350/220 antigen. Hum. Immunol. 62:2001;362-367.
26. Zhang X., Boyar W., Toth M.J., Wennogle L., Gonnella N.C. Structural definition of the C5a C terminus by two-dimensional nuclear magnetic resonance spectroscopy. Proteins. 28:1997;261-267.
27. Raffetseder U., Roper D., Mery L., Gietz C., Klos A., Grotzinger J., Wollmer A., Boulay F., Kohl J., Bautsch W. Site-directed mutagenesis of conserved charged residues in the helical region of the human C5a receptor. Arg206 determines high-affinity binding sites of C5a receptor. Eur. J. Biochem. 235:1996;82-90.